Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlpha Growth Regulatory News (ALGW)

Share Price Information for Alpha Growth (ALGW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.30
Bid: 2.20
Ask: 2.40
Change: 0.45 (24.32%)
Spread: 0.20 (9.091%)
Open: 1.85
High: 2.30
Low: 1.85
Prev. Close: 1.85
ALGW Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Update

20 Jul 2020 07:00

RNS Number : 4101T
Alpha Growth PLC
20 July 2020
 

Alpha Growth plc

("Alpha", or the "Company")

Corporate Update

 

Alpha Growth plc (LSE: ALGW), the financial services specialist in the growing Senior Life Settlement ("SLS") asset class is pleased to provide the market with a corporate update on the Company's business. This release provides an update on the Impact of Covid-19 and addresses shareholder questions that the Company has received since its last update on 27th April 2020.

 

BlackOak Alpha Growth Fund - Since the end of April 2020, the Company on the back of successful marketing activity, the Fund has seen a significant rise in interest from registered investment advisors ("RIAs") in the USA and family offices. The Company is marketing through email and telephone to over forty-two thousand RIAs which currently are in the Company's CRM system (with this number increasing). The open, click, and reply rates have increased along with the number of investment conference calls per week. Next steps involve the RIA conducting due diligence on the Fund and manager. Several major RIAs have commenced this detailed step with the Company.

 

The Company will be reporting fee revenue received in relation to the Fund for its fiscal year ending in August.

 

Separate Managed Accounts and Sub-advisory roles - The Company has entered into discussions with sponsors of proprietary funds to manage the longevity assets within those funds or what are known as separate managed accounts.

 

When shareholders noticed on a third party website that Danny Swick, Alpha's COO, would be speaking at a family office conference in February, as the portfolio manager of a longevity fund, it provided a good example of the Company's activity in this part of the business. The web posting was made by the fund's sponsors and the RIA hosting the conference intended that the conference would be the initial unveiling of a new fund.

The new fund is an open ended limited partnership (which is a typical structure) and to launch involves not only the required legal documentation but also establishing the investment strategy with the sponsor, coordination of marketing material, investor meetings and asset management processes, among other matters. Alpha's role is to act as an advisor on all of the above functions and its executives take on certain roles in the fund in title only through its agreement with the sponsor. The cost of all the above functions and raising the capital is the responsibility of the fund's sponsors. Alpha would collect a percentage of the management and performance fee for its services once a fund is launched. In the ordinary course, such mandates typically take between nine to twelve months to get to the launch stage if all goes well, however the escalation of Covid-19 has delayed a launch and will be revisited. The Company will only make a further announcement on its engagement once the sponsor has officially approved the launch.

 

Warehouse Loan/Short Term Credit Facility - In early July, the Company resumed discussions with the counterparty to determine the next steps in the establishment of the Warehousing facility. The counterparty noted that they are looking forward now and that the internal issues they faced due to Covid-19's effect on their business are being managed. The Company will provide further updates as discussions progress.

 

Development of New Strategy - Alpha Growth is pleased to announce the development of the Alpha Growth & Income ("AGI") strategy, a dynamic response to developments in the marketplace over the past several months. The strategy is a combination of life settlements and life contingent structured settlements hedged by a life insurance policy that is suitable for investors seeking cashflow and growth, funded in either a separate managed account or as a co-mingled fund with a minimum investment of $50 million. A structured settlement is an arrangement whereby the plaintiff, usually aggrieved in an accident, agrees to resolve a tort claim by receiving periodic payments under an annuity contract on an agreed schedule rather than a lump-sum payment at the time of settlement. Payments are typically guaranteed but can become life contingent after the end of the guaranteed payment period, making it a longevity asset and is payable by an insurance company. A structured settlement can provide positive cashflow during its hold period. The AGI can provide the investor an annual cash flow through the structured settlement asset and growth in the principal invested through the life settlement asset. As part of the development process, it was introduced to select institutional parties.  The Company will continue to promote and seek clients for this strategy.

 

Operational Update

· The Company continues to maintain a lean operating structure

· Sufficient working capital for its current strategies

· Engaged with Proactive Investors a financial media portal to expand its outreach to existing shareholders and prospective clients

· Alpha has been added to the Pello Capital Spotlight page to provide additional sources of information to shareholders

· Planned improvements to the Company website

· Planned hire of additional director put on hold until increase in corporate activity

 

The impact of Covid-19 has no doubt had an effect on the timing of various counterparties to transact with the Company. As previously stated, there will be an impact on Company's financial results in FY20 if delays should continue for an extended period of time.

 

The Company is still confident that, particularly with record low interest rates, continued volatility in the equity markets and the non-correlation of SLS assets, it will be able to continue those discussions in the near terms, and also take advantage of further opportunities as and when they arise.

 

The Directors thank the shareholders for their continuing support and look forward to making progress on all strategies in as timely a manner as possible. Further details are provided on the Company website www.algwplc.com.

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

For more information, please visit www.algwplc.com or contact the following:

 

Alpha Growth plc: Gobind Sahney, Executive Chairman +44 (0) 20 3959 8600 info@algwplc.com

 

About Alpha Growth plc

Specialist in Longevity Assets

Alpha Growth plc is a financial advisory business providing specialist consultancy, advisory, and supplementary services to institutional and qualified investors globally in the multi-billion dollar market of longevity assets. Building on its well-established network, the Alpha Growth Group has a unique position in the longevity asset services and investment business, as a listed entity with global reach. The Group's strategy is to expand its advisory and business services via acquisitions and joint ventures in the UK and the US to attain commercial scale and provide holistic solutions to alternative institutional investors who are in need of specialised skills and unique access to deploy their financial resource in longevity assets.

 

SLS Assets and Non-correlation

A SLS refers to the sale of an existing life insurance policy to a third party for a cash payment. Such a payment will be in excess of the policy's surrender value, but less than its face value. After the sale, the purchaser becomes the policy's beneficiary and assumes payment of its premiums. There are many reasons why policy holders may choose to sell their life insurance policies and sales are usually only undertaken when the insured person doesn't have a known life-threatening illness. The SLS provides individuals with policies the option to realise value from an asset under a regulated transaction. As a longevity asset, the SLS is non-correlated to the real estate, equity capital and commodity markets. Its value is a function of time because as time passes the value gets closer to the face value of the policy. Hence creating a steady increase in the net asset value of the investment. This makes it highly attractive to investors wishing to counteract volatility within an investment portfolio and add yield.

 

Note: The Company only advises on and manages SLS Assets that originate in the USA where the SLS market is highly regulated.

 

Forward Looking Statements Disclaimer

Certain statements, beliefs and opinions in this document are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward- looking statements, which speak only as of the date of this document. Readers should not treat the contents of this document as advice relating to legal, taxation or investment matters, and are to make their own assessments concerning these and other consequences, including the merits of information and the risks. Readers of this announcement are advised to conduct their own due diligence and agree to be bound by the limitations of this disclaimer.

 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDKKOBBBBKBPOD
Date   Source Headline
10th Feb 20208:00 amRNSResult of AGM
31st Dec 20197:00 amRNSPublication of the 2019 Annual Report
17th Dec 20197:00 amRNSTrack Record Review, Placing & Total Voting Rights
2nd Dec 20197:00 amRNSAdvancement of Warehousing SPV and Subscription
11th Nov 20197:00 amRNSAppointments and Board changes
20th Sep 201911:46 amRNSSecond Price Monitoring Extn
20th Sep 201911:45 amRNSPrice Monitoring Extension
18th Sep 20193:31 pmRNSAlpha Growth - Holding(s) in Company
12th Aug 20197:00 amRNSHolding(s) in Company
15th Jul 20197:00 amRNSCorporate Update
2nd Jul 20199:14 amRNSHolding(s) in Company
5th Jun 20197:00 amRNSIssue of Equity & TVR
16th May 201912:00 pmRNSHolding(s) in Company
10th May 20192:16 pmRNSPublication of Prospectus
3rd May 201911:05 amRNSSecond Price Monitoring Extn
3rd May 201911:00 amRNSPrice Monitoring Extension
30th Apr 20197:20 amRNSProposed Placing
30th Apr 20197:00 amRNSBlackOak Alpha Growth Fund Launch
29th Apr 20194:00 pmRNSInterim Results
18th Apr 20192:00 pmRNSPrice Monitoring Extension
29th Mar 20192:28 pmRNSHolding(s) in Company
6th Mar 20197:00 amRNSBoard Changes
4th Mar 201910:10 amRNSResult of AGM
4th Mar 20197:00 amRNSCorporate Update
1st Mar 20197:00 amRNSAcquisition of Colva
20th Feb 201910:28 amRNSIssue of Equity
13th Feb 20197:00 amRNSAlpha Growth Investor Meeting
7th Feb 20197:00 amRNSAlpha Growth - Notice of Annual General Meeting
30th Jan 20197:00 amRNSAcquisition: Completion of ALM Acquisition
24th Dec 201810:52 amRNSFinal Results
21st Nov 20187:00 amRNSSL Investment Management Joint Venture
15th Nov 201811:36 amRNSHolding(s) in Company
24th Sep 20181:59 pmRNSHolding(s) in Company
17th Sep 20184:40 pmRNSSecond Price Monitoring Extn
17th Sep 20184:35 pmRNSPrice Monitoring Extension
17th Sep 20182:05 pmRNSSecond Price Monitoring Extn
17th Sep 20182:00 pmRNSPrice Monitoring Extension
17th Sep 201812:18 pmRNSHolding(s) in Company
17th Sep 20187:00 amRNSIssue of Equity and Director/PDMR Dealing
4th Sep 20185:14 pmRNSHolding(s) in Company
30th Aug 201812:16 pmRNSHolding(s) in Company
24th Aug 201812:59 pmRNSNotification of Major Holdings
18th Jul 20187:00 amRNSAcquisition of ALM
13th Jun 20187:00 amRNSHolding(s) in Company
8th Jun 20187:00 amRNSEngagement of Devonshire Warwick, Investor Event
1st Jun 20187:00 amRNSAppointment of Chief Operating Officer
11th May 20184:03 pmRNSHolding(s) in Company
30th Apr 20181:00 pmRNSInterim results
12th Mar 20182:13 pmRNSAppointment of Corporate Advisor and Broker
6th Feb 20187:00 amRNSLaunch of Innovative Hybrid Product

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.